Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Therapeutic potential of human induced pluripotent stem cells and renal progenitor cells in experimental chronic kidney disease

Fig. 3

Quantitative real-time PCR for RPC (day 16), EB (day 3), and hiPSC (day 0). EBs showed an increased expression of a PAX2 (p = 0.001 vs. RPC, p = 0.002 vs. hiPSC), b WT1 (p = 0.03 vs. RPC, p = 0.002 vs. hiPSC), c SIX2 (p = 0.0001 vs. RPC, p = 0.0001 vs. hiPSC), and d SALL1 (p = 0.05 vs. RPC, p = 0.01 vs. hiPSC). hiPSCs showed a decreased expression of e NPHS1 (p = 0.001 vs. human kidney) and f SYNPO (p = 0.03 vs. RPC, p = 0.01 vs. EB, p = 0.0002 vs. human kidney) on day 0, whereas the expression of both e NPSH1 and f SYNPO increased in RPCs on day 16. The pluripotency marker gene g OCT4 had a decreased expression during the differentiation process (p = 0.04 hiPSC vs. EB, p = 0.02 hiPSC vs. RPC). *p value < 0.05

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512